1. Artificial nutrition in patients with cancer has no impact on tumour glucose metabolism: Results of the PETANC Study
- Author
-
Anne Fallières, Marie-Claude Eberlé, N. Flori, Hélène de Forges, Pierre Senesse, Julien Fraisse, Raphael Tetreau, Jean-Pierre Pouget, Sophie Guillemard, Pierre-Olivier Kotzki, Lore Santoro, Emmanuel Deshayes, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CRLCC Val d'Aurelle - Paul Lamarque, Unité de biostatistiques, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), and CCSD, Accord Elsevier
- Subjects
Blood Glucose ,Male ,0301 basic medicine ,medicine.medical_specialty ,Cachexia ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,030209 endocrinology & metabolism ,Carbohydrate metabolism ,Critical Care and Intensive Care Medicine ,Gastroenterology ,Enteral administration ,Eating ,03 medical and health sciences ,0302 clinical medicine ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Fluorodeoxyglucose F18 ,Positron Emission Tomography Computed Tomography ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Nutritional support ,Prospective cohort study ,Aged ,Cancer ,Cancer staging ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,030109 nutrition & dietetics ,Nutrition and Dietetics ,medicine.diagnostic_test ,business.industry ,Tumour growth ,Middle Aged ,medicine.disease ,3. Good health ,Glucose ,Parenteral nutrition ,Head and Neck Neoplasms ,Positron emission tomography ,Female ,(18)F-FDG PET/CT ,business ,Supportive care ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Summary Background & aims Nutrition support is recommended in cachexic patients with cancer. However, there is no clear evidence about its impact on tumour growth. Glycolysis, which is usually higher in cancer than normal cells, can be monitored by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging that is widely used for cancer staging and therapy efficacy assessment. Here, we used 18F-FDG PET/CT imaging to investigate whether artificial nutrition has an impact on tumour glucose metabolism in patients with cancer and cachexia. Methods This prospective study included ten patients with histologically proven head and neck or oesophageal cancer. All patients underwent 18F-FDG PET/CT imaging at baseline and after (parenteral and/or enteral) nutrition support on average for 7 days. Tumour glucose metabolism changes were evaluated using static (SUVmax, SUVmean and SULpeak) and dynamic (glucose metabolic rate and transport constant rates, k) parameters computed from the 18F-FDG PET/CT data. Results Artificial nutrition (median energy intake of 21.83 kcal/kg/day [13.16–45.90], protein intake of 0.84 g/kg/day [0.56–1.64]) was administered. Eight patients (80%) received enteral nutrition and two patients (20%) parenteral support. Comparison of 18F-FDG PET/CT parameters did not highlight any significant difference in tumour glucose metabolism before and after the period of nutrition support. Conclusions In cachexic patients with head and neck or oesophageal cancer, nutrition support administered according to the current guidelines shows no impact on tumour glucose metabolism, assessed by 18F-FDG PET/CT.
- Published
- 2019
- Full Text
- View/download PDF